Comparative Pharmacology
Head-to-head clinical analysis: ANTIZOL versus PROTAMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIZOL versus PROTAMINE SULFATE.
ANTIZOL vs PROTAMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the oxidation of ethanol to acetaldehyde. It also inhibits the metabolism of ethylene glycol and methanol to their toxic metabolites.
Protamine sulfate is a cationic protein that binds to heparin, an anionic anticoagulant, forming a stable complex that neutralizes heparin's anticoagulant activity. It also has mild anticoagulant properties of its own.
Initial: 15 mg/kg IV over 10 minutes, then 3 mg/kg IV every 4 hours for 2 doses, then 3 mg/kg IV every 6 hours for 4 doses.
1 mg IV per 100 units of heparin to be neutralized, administered slowly (not exceeding 5 mg/min) with continuous monitoring. Maximum single dose: 50 mg.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours in adults. Clinical context: Dose adjustment recommended in severe renal impairment (CrCl <30 mL/min) due to prolonged half-life.
Complex with heparin: 4–5 minutes (free protamine: 7.4 minutes). Clinically, the anticoagulant reversal effect is rapid but may be transient due to heparin rebound.
Renal: 80-95% as parent drug and metabolites. Fecal: <5%. Biliary excretion is negligible.
Primarily renal excretion (heparin-protamine complexes are cleared by the reticuloendothelial system; elimination is largely independent of renal function). <5% excreted unchanged in urine.
Category C
Category A/B
Antidote
Antidote